Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glaucoma, Open Angle Clear all
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT01279083
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure

NCT01560975
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
Interventions
SENSIMED Triggerfish®
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

NCT01336569
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost 0.004%/timolol maleate 0.5% fixed combination
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2013 · Synced Sep 27, 2026, 3:14 AM EDT
Suspended Phase 3 Interventional

SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma

NCT00382395
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open Angle
Interventions
SOLX Gold Shunt GMS-plus, Ahmed FP7 Glaucoma Valve
Device
Lead sponsor
SOLX, Inc.
Industry
Eligibility
21 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
9
States / cities
Petaluma, California • Littleton, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Sep 27, 2026, 3:14 AM EDT
Terminated No phase listed Observational

Imaging Lens Deposits in Exfoliation Syndrome

NCT02042703
View directory record Official record
Conditions
Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts
Interventions
anterior segment OCT
Device
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 27, 2026, 3:14 AM EDT
Recruiting Not applicable Interventional

Hydrus® Microstent New Enrollment Post-Approval Study

NCT04553523
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Hydrus Microstent, Cataract surgery, Monofocal IOL
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
22
States / cities
Irvine, California • Sacramento, California • Loveland, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

NCT00441883
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
Interventions
PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

NCT00853905
View directory record Official record
Conditions
Glaucoma
Interventions
Triesence, balanced salt solution BSS
Drug
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 27, 2026, 3:14 AM EDT
Enrolling by invitation No phase listed Observational

A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma

NCT07520175
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
AlloSpan Canal Platform Bio-Reinforced Canaloplasty
Procedure
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Chico, California • Petaluma, California • Coon Rapids, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Phase 1 Interventional

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

NCT01670266
View directory record Official record
Conditions
Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG)
Interventions
ONO-9054, Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
3
States / cities
Costa Mesa, California • Newport Beach, California • Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Phase 4 Interventional

Assessing Cosopt Switch Patients

NCT00273442
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome, Glaucoma, Pigmentary
Interventions
timolol maleate, dorzolamide/timolol maleate fixed combination
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Bourbonnais, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Sep 27, 2026, 3:14 AM EDT
Not yet recruiting Not applicable Interventional

Effect of Late Ripcord Removal From Glaucoma Drainage Device

NCT07803536
View directory record Official record
Conditions
GLAUCOMA 1, OPEN ANGLE, D (Disorder), Glaucoma
Interventions
Ripcord removal
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 27, 2026, 3:14 AM EDT
Not listed Not applicable Interventional

A Single Center Proof Of Concept Study To Assess Intra And Perioperative Safety Profile Of OMNI Surgical System

NCT04530084
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
OMNI Surgical System
Device
Lead sponsor
Mark Gallardo, MD
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 27, 2026, 3:14 AM EDT
Completed No phase listed Observational

Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies

NCT02151318
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma

NCT04632329
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Negative Pressure Treatment via the Mercury Multi-Pressure Dial
Device
Lead sponsor
Equinox
Industry
Eligibility
22 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Sioux Falls, South Dakota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Phase 2 Interventional

24-hour Efficacy of AR-12286

NCT01330979
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-12286 0.5% Ophthalmic Solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Phase 2 Interventional

A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT00051194
View directory record Official record
Conditions
Glaucoma, Open-angle, Ocular Hypertension
Interventions
Combination IOP Lowering Therapy
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2012 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Phase 2 Interventional

A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma

NCT02014142
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma
Interventions
Latanoprost Punctal Plug Delivery System (L-PPDS)
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Chandler, Arizona • Phoenix, Arizona • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 27, 2026, 3:14 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Combined Phacoemulsification With iStent Inject W Versus Hydrus for Mild to Moderate Open Angle Glaucoma

NCT05583591
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Combined cataract surgery with Hydrus microstent, Combined cataract surgery with iStent Inject W
Device
Lead sponsor
Diablo Eye Associates
Industry
Eligibility
60 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 27, 2026, 3:14 AM EDT
Active, not recruiting No phase listed Observational

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

NCT05506423
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
CycloPen Cyclodialysis System
Device
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Phase 2 Interventional

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01917383
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Trabodenoson, Latanoprost, Timolol
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bristol, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT04742283
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 27, 2026, 3:14 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

NCT06369077
View directory record Official record
Conditions
Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions
dorzolamide/timolol
Drug
Lead sponsor
CT Glaucoma Associates
Other
Eligibility
25 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 27, 2026, 3:14 AM EDT
Completed Phase 1 Interventional

NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement

NCT01408472
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
NT-501 CNTF Implant
Drug
Lead sponsor
Jeffrey L Goldberg
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Sep 27, 2026, 3:14 AM EDT